Market Overview

Regeneron, Sanofi Announce FDA Has Accepted For Review BLA For Sarilumab


Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) jointly announced Friday morning that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for sarilumab.

Regeneron noted that the BLA for sarilumab contains data from around 2,500 adults with active, moderate or severe rheumatoid arthritis who had an inadequate response to prior treatment regimens.

"The goal of the ongoing global clinical development program is to evaluate the safety and efficacy of subcutaneous sarilumab, either as monotherapy or in combination with conventional disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX), in reducing the signs and symptoms and inhibiting the radiographic progression of RA," Regeneron stated.

Shares of Regeneron were trading higher by 0.63 percent at $505.11 Friday morning, while shares of Sanofi were trading lower by 0.58 percent at $41.09.


Related Articles (REGN + SNY)

View Comments and Join the Discussion!

Posted-In: Biologics License Application BLA Regeneron rheumatoid arthritisNews Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at